POLICY: Bone Modifiers – Zoledronic Acid IV (Zometa) [Zometa® {zoledronic acid injection}, – Novartis, generic]

APPROVAL DATE: 02/27/2019

OVERVIEW
Zoledronic acid injection (Zometa) is indicated for the treatment of hypercalcemia of malignancy, defined as an albumin-corrected calcium (cCa) ≥ 12 mg/dL (3.0 mmol/L). Zoledronic acid injection (Zometa) is also indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. A limitation of use is that the efficacy and safety of zoledronic acid injection (Zometa) in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumor-related conditions have not been established. Prostate cancer should have progressed after treatment with at least one hormonal therapy.1 Another formulation of zoledronic acid injection is available, Reclast®, but is not included in this policy.2

Other Uses with Supportive Evidence
Data are available with zoledronic acid injection (Zometa) regarding off-label uses. One example is to prevent bone loss in patients with breast cancer receiving aromatase inhibitor therapy. Aromatase inhibitor therapy prevents peripheral production and suppress estrogen levels and can lead to accelerated bone loss beyond what would naturally occur in women.3,4 This can place the patient at an risk for having a fracture. A review on the management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer5 states that zoledronic acid injection (Zometa) [4 mg every 6 months] is the preferred agent for preventing and treatment aromatase inhibitor bone loss.4 Zoledronic acid injection (Zometa) has been studied and shown benefits in postmenopausal women receiving adjuvant letrozole for breast cancer.5-6

Zoledronic acid injection (Zometa) also has utilized to prevent bone loss in patients with prostate cancer who are receiving androgen deprivation therapy (ADT). ADT is associated with a variety of adverse events, including osteoporosis. The National Comprehensive Cancer Network (NCCN) clinical practice guidelines regarding prostate cancer (version 4.2018 – August 15, 2018)7 cite zoledronic acid as an option to increase bone density, a surrogate for fracture risk, during ADT for prostate cancer. Zoledronic acid injection (Zometa) has led to bone mineral density increases in patients with prostate cancer who are receiving androgen deprivation therapy.8,9 A clinical practice guideline for osteoporosis in men from the Endocrine Society9 recommends pharmacological treatment for osteoporosis for men with prostate cancer receiving ADT who have a high risk of fracture.

Zoledronic acid injection (Zometa) has utility in premenopausal patients with breast cancer who have developed ovarian failure. Chemotherapy-induced ovarian failure is an adverse effect associated with some adjuvant chemotherapy and can lead to rapid bone loss.10-11 Studies have demonstrated zoledronic acid injection (Zometa) to be efficacious in preserving bone mineral density in premenopausal women with breast cancer who developed ovarian failure due to adjuvant chemotherapy.

POLICY STATEMENT
Prior authorization is recommended for medical benefit coverage of zoledronic acid injection (Zometa). Approval is recommended for those who meet the Criteria and Dosing for the listed indication(s). Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration

02/27/2019
noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with zoledronic acid injection (Zometa) as well as the monitoring required for adverse events and long-term efficacy approval requires zoledronic acid injection (Zometa) to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**RECOMMENDED AUTHORIZATION CRITERIA**
Coverage of zoledronic acid injection (Zometa) is recommended in those who meet the following criteria:

**FDA-Approved Indications**

<table>
<thead>
<tr>
<th>1. Hypercalcemia of Malignancy.</th>
<th>Approve for 1 month if the patient meets the following criteria (A and B):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A) The patient has a current malignancy; AND</td>
</tr>
<tr>
<td></td>
<td>B) The patient’s albumin-corrected calcium (cCa) is ≥ 11.5 mg/dL.</td>
</tr>
</tbody>
</table>

**Dosing.** Approve 4 mg given as a single dose intravenous (IV) infusion for up to two doses with the second dose given separated by a minimum of 7 days from the first dose.

<table>
<thead>
<tr>
<th>2. Multiple Myeloma (Treatment).</th>
<th>Approve for 1 year if the agent is prescribed by or in consultation with a hematologist or oncologist.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dosing.</strong></td>
<td>Approve up to 4 mg by intravenous infusion administered no more frequently than once every 3 weeks.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. Treatment of Bone Metastases From Solid Tumors (e.g., Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Renal Cell Cancer, Small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastrointestinal/Genitourinary Cancer, Head and Neck Cancer).</th>
<th>Approve for 1 year if the patient meets all of the following criteria (A, B, and C):</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) The agent must be prescribed by, or in consultation with, a hematologist or oncologist; AND</td>
<td></td>
</tr>
<tr>
<td>B) The patient has bone metastases; AND</td>
<td></td>
</tr>
<tr>
<td>C) Patients with prostate cancer have received at least one hormonal therapy (e.g., Lupron Depot®, Eligard® [leuprolide acetate for injectable suspension], Trelstar® [triptorelin pamoate for injectable suspension], or Zoladex® [goserelin implant]).</td>
<td></td>
</tr>
</tbody>
</table>

**Dosing.** Approve up to 4 mg by intravenous infusion administered no more frequently than once every 3 weeks.

**Other Uses with Supportive Evidence**

<table>
<thead>
<tr>
<th>4. Prevention of Bone Loss (To Increase Bone Mass) in Patients with Breast Cancer Receiving Aromatase Inhibitor Therapy.</th>
<th>Approve for 1 year if the patient meets the following criteria (A and B):</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) The patient has breast cancer that is not metastatic to bone; AND</td>
<td></td>
</tr>
<tr>
<td>B) The patient is receiving an aromatase inhibitor therapy (e.g., anastrozole, letrozole, and exemestane).</td>
<td></td>
</tr>
</tbody>
</table>

**Dosing.** Approve up to 4 mg by intravenous infusion no more frequently than once every 6 months.
5. **Prevention of Bone Loss (to Increase Bone Mass) in Patients with Prostate Cancer Who are Receiving Androgen Deprivation Therapy (ADT).** Approve 1 year if the patient meets the following criteria (A and B):
   A) The patient has prostate cancer that is not metastatic to bone; AND
   B) The patient is currently receiving androgen deprivation therapy (e.g., Lupron Depot\textsuperscript{®} [leuprolide for depot suspension], Eligard\textsuperscript{®} [leuprolide acetate for injectable suspension], Trelstar\textsuperscript{®} [triptorelin pamoate for injectable suspension], or Zoladex\textsuperscript{®} [goserelin implant]), or the patient has undergone bilateral orchiectomy.

   **Dosing.** Approve up to 4 mg by intravenous infusion no more frequently than once every 3 months.

6. **Prevention of Bone Loss (to Increase Bone Mass) in Premenopausal Patients with Breast Cancer Who Have Developed Ovarian Failure.** Approve for 1 year if the patient meets the following criteria (A and B):
   A) The patient is a premenopausal patient with breast cancer that is not metastatic to bone; AND
   B) The patient has received adjuvant chemotherapy and has developed ovarian failure.

   **Dosing.** Approve up to 4 mg by intravenous infusion no more frequently than once every 3 months.

---

**CONDITIONS NOT RECOMMENDED FOR APPROVAL**
Zoledronic acid injection (Zometa) has not been shown to be effective or there are limited or preliminary data, or potential safety concerns, that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions are provided below.

1. Coverage is not recommended for circumstances *not* listed in the *Recommended Authorization Criteria*. Criteria will be updated as new published data are available.
REFERENCES

Bone Modifiers – Zoledronic Acid IV (Zometa) CC

Utilization Review Policy

**HISTORY**

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes*</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual revision</td>
<td>Changed the name to add “Bone Modifiers” to the title of Zometa CC.</td>
<td>02/14/2018</td>
</tr>
<tr>
<td>Annual revision</td>
<td>The name of the policy was changed from Bone Modifiers – Zometa to Bone Modifiers – Zoledronic Acid IV (Zometa) to reflect generic availability of the product. For all indications, except hypercalcemia of malignancy, the requirement that the creatinine clearance be ≥ 30 mL/min, which was cited in the labs/diagnostic section, was removed from the policy. Likewise, the criteria in the conditions not recommended for approval section that required the creatinine clearance to be &lt; 30 mL/min was removed, which applies to all indications, except for hypercalcemia of malignancy. Also, the criteria listed in the conditions not recommended for approval section that stated that concurrent use of Zometa with the Reclast formulation of zoledronic acid injection is not recommended was removed. For the indication regarding hypercalcemia of malignancy, the duration of therapy was changed to 1 month. Previously, two doses, administered 7 days apart, were permitted for this use. Also, for hypercalcemia of malignancy, the reference to “adults” was removed from the dosing section. For the treatment of multiple myeloma, the approval duration was changed from 6 months to 1 year. The dosing for multiple myeloma was changed to approve up to 4 mg by intravenous infusion administered no more frequently than once every 3 weeks. Previously, the dosages were cited as 4 mg or less by intravenous infusion once every 3 to 4 weeks or once every 12 weeks. For the treatment of bone metastases from solid tumors, the approval duration was changed from 6 months to 1 year. For the criteria regarding treatment of bone metastases from solid tumors, the requirement that the patient have bone metastases which were “confirmed by radiographic or imaging studies” was removed from the criteria, as well as from the labs/diagnostic sections. The dosing for the treatment of bone metastases from solid tumors was changed to approve up to 4 mg by intravenous infusion administered no more frequently than once every 3 weeks. Previously, the dosages were cited as 4 mg or less by intravenous infusion once every 3 to 4 weeks or once every 12 weeks. For the prevention of bone loss in patients with breast cancer receiving aromatase inhibitor therapy, the approval duration was changed from 6 months to 1 year. The dosing for this use was changed from “The dose is 4 mg or less by intravenous infusion once every 6 months” to “approve up to 4 mg by intravenous infusion no more frequently than once every 6 months”. For the prevention of bone loss in patients with prostate cancer who are receiving androgen deprivation therapy, the approval duration was changed from 6 months to 1 year. The dosing for this use was changed from “The dose is 4 mg or less by intravenous infusion once every 3 to 6 months” to “approve up to 4 mg by intravenous infusion no more frequently than once every 3 months”. For the prevention of bone loss in premenopausal patients with breast cancer who have developed ovarian failure, the approval duration was changed from 6 months to 1 year. The dosing for this use was changed from “The dose is 4 mg or less by intravenous infusion once every 3 to 6 months” to “approve up to 4 mg by intravenous infusion no more frequently than once every 3 months”. For all indications the following sections were removed: initial approval/extended approval, duration of therapy, and labs/diagnostics. The Waste Management section of the policy was deleted, as well as Appendix A and B that detailed calculating albumin-corrected calcium (cCa) and creatinine clearance (CrCl).</td>
<td>02/27/2019</td>
</tr>
</tbody>
</table>

TAC – Therapeutic Assessment Committee.